비스타젠 테라퓨틱스VTGN 주가

♻️ 재탕[8-K] 중대 사건 — 8-K

[3] 3

[4] 내부자 거래

[SCHEDULE 13G/A] SCHEDULE 13G/A

Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Vistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called...

Vistagen announces preliminary positive data in ongoing open-label extension portion of PALISADE-3 phase 3 study of fasedienol for the acute treatment of social anxiety disorder

VistaGen Therapeutics Inc: Vistagen announces preliminary positive data in ongoing open-label extension portion of PALISADE-3 phase 3 study of fasedienol for the acute treatment of social anxiety...

Vistagen Announces Its Data From PALISADE-3 Phase 3 Trial Of Fasedienol Demonstrates Well-Toleration, No Drug-Related Safety Concerns

Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines,

♻️ 재탕[8-K] 중대 사건 — 8-K

♻️ 재탕Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

SOUTH SAN FRANCISCO - Vistagen , a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal...

Vistagen Completes Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder, With Topline Results Expected In Q2

Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines,